113 results on '"Roche, Nicolas"'
Search Results
2. Late Breaking Abstract - Baseline characteristics impact on asthma exacerbation risk: individual patient trial data analysis
3. Blood inflammatory phenotypes and clinical characteristics as determinants of persistent asthma in the Constances cohort
4. Blood basophils, nocturnal cough and asthma in the Constances cohort
5. CAT versus mMRC to allocate COPD patients to clinically relevant phenotypes identified using Classification and Regression Trees
6. Late Breaking Abstract - Consensus quality standard for implementing inhaler regimen switch in patients with respiratory disease
7. Efficacy and safety of oral corticosteroids to treat outpatients with acute exacerbations of COPD in primary care: a multicentre pragmatic randomised controlled study.
8. Update June 2022: management of hospitalised adults with coronavirus disease-19 (COVID-19): a European Respiratory Society living guideline [editorial]
9. Update March 2022: management of hospitalised adults with coronavirus disease-19 (COVID-19): a European Respiratory Society living guideline [editorial]
10. European Respiratory Society clinical practice guidelines: methodological guidance [editorial]
11. Late Breaking Abstract - Pneumonia risk in COPD patients initiating extrafine Fixed Dose Combination (FDC) with beclometasone dipropionate (ef-FDC-BDP) versus long-acting bronchodilators (LABD)
12. Late Breaking Abstract - Comparing pneumonia risk in COPD patients initiating Fixed Dose Combination (FDC) inhaler comprising extrafine beclometasone dipropionate versus fluticasone
13. Impact of COVID-19 on treatments’ dispensations for chronic airways diseases in France
14. Dyspnea-induced Limitation (DYSLIM), a self-administered questionnaire to evaluate dyspnea-related activity limitation in respiratory disease>
15. Burden of asthma by treatment step in the French CONSTANCES general population cohort
16. Blood inflammatory phenotypes of asthma in the Constances cohort
17. Real-life evidence in ERS clinical practice guidelines: from foes to friends [editorial]
18. Expanding the spectrum of European Respiratory Society official scientific documents: short documents complement clinical practice guidelines, statements and technical standards [editorial]
19. Guidance production before evidence generation for critical issues: the example of COVID-19 [editorial]
20. Antibiotic prophylaxis in lung resection surgery
21. Influenza and pneumococcal vaccination in patients with COPD
22. Sex differences in COPD outcome in 5,355 women with COPD: A new analysis of the 3CIA study
23. The impact of therapeutics on mortality in hospitalised patients with COVID-19: systematic review and meta-analyses informing the European Respiratory Society living guideline.
24. Risk charts of five-year mortality in COPD patients
25. Association between occupational exposures to solvents and airway obstruction in the CONSTANCES cohort
26. Occupational exposures to solvents and asthma in the Constances cohort
27. Differentiating asthma from chronic obstructive pulmonary disease (COPD) in medico-economic databases: myth or reality?
28. Burden and drivers of severe hypoxemia in real life patients with stable COPD
29. How can we minimise the use of regular oral corticosteroids in asthma?
30. Late Breaking Abstract - Blood eosinophil counts and treatment response in COPD: analyses of IMPACT
31. Osteoporosis onset in patients prescribed ICS for COPD: matched cohort study
32. Association between ICS therapy for COPD and diabetes onset and progression
33. Reduction in fatal events with extrafine inhaled corticosteroid (ICS)-containing medications: results of stratified safety pooled analysis of the TRILOGY, TRINITY and TRIBUTE studies.
34. Comparison of dual vs triple therapies in patients hospitalized for COPD in France: a claims data study
35. Relation between gender and survival among real-life COPD patients
36. Observational study of adherence to indacaterol/glycopyrronium 110/50µg o.d. (IND/GLY) in COPD
37. Asthma control and COPD symptom burden: results from a multi-country observational study (SPRINT) in patients using fixed dose combination (FDC) inhalers
38. DuoResp Spiromax adherence, satisfaction and ease of use: findings from a multi-country observational study in patients with asthma and COPD (SPRINT)
39. Determinants of the 6 minute walking distance and exercise desaturations in COPD: relationships with comorbidities
40. Indacaterol/glycopyrronium (IND/GLY) is cost-effective compared with salmeterol/fluticasone (SFC) in Swedish chronic obstructive pulmonary disease (COPD) patients
41. Indacaterol/glycopyrronium (IND/GLY) improves lung function, health status and rescue medication use vs salmeterol/fluticasone (SFC) independent of symptom response: The FLAME study
42. Real-life evaluation of budesonide/formoterol (DuoResp Spiromax) for the management of asthma and COPD in the UK
43. COPD exacerbations significantly impact quality of life as measured by SGRQ-C total score: results from the FLAME study
44. Applicability of randomized controlled trials (RCTs) results to real-life patients in COPD
45. Estimating the number of patients’ needed to treat (NNT) with indacaterol/glycopyrronium to prevent COPD exacerbations: Results from the FLAME study
46. Efficacy of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) on exacerbations and health status in GOLD Group D COPD patients: The FLAME study
47. Modeling future COPD epidemiology
48. Automated video analysis of movements in learning the inhaled administration of drugs by patients: A validation study
49. LATE-BREAKING ABSTRACT: An algorithm for the identification of clinical COPD phenotypes in daily practice
50. Cardiovascular (CV) safety of indacaterol/glycopyrronium (IND/GLY) compared with salmeterol/fluticasone combination (SFC) in moderate-to-very severe COPD patients with prior exacerbations: The FLAME study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.